Literature DB >> 3254822

The US National Cholesterol Education Program. Adult treatment guidelines.

S B Hulley1.   

Abstract

The National Institutes of Health (NIH) have begun a new National Cholesterol Education Program (NCEP). Modelled on the successful High Blood Pressure Education Program of the last 15 years, the NCEP has the goals of developing education approaches on how to manage blood cholesterol in the general population and of encouraging health professionals and the public to implement these approaches widely across the United States. The NCEP treatment guidelines recommend that all adults have a blood cholesterol measurement at least once every 5 years. Patients with levels greater than 5.2 mmol/L (200 mg/dl) [confirmed by a second blood cholesterol measurement] should be advised to adopt a Step 1 fat-controlled diet. Patients with cholesterol exceeding 6.2 mmol/L (240 mg/dl) are candidates for intensive treatment with a Step 2 diet and sometimes drugs, as are those in the 5.2 to 6.2 mmol/L (200 to 240 mg/dl) range who are at especially high risk because they already have coronary artery disease and/or 2 other risk factors. However, drugs for lowering blood cholesterol should be used only when the indication has been confirmed by measuring LDL-cholesterol, and as a supplement to the dietary treatment.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3254822     DOI: 10.2165/00003495-198800363-00021

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  9 in total

1.  Consensus conference. Lowering blood cholesterol to prevent heart disease.

Authors: 
Journal:  JAMA       Date:  1985-04-12       Impact factor: 56.272

2.  The 1984 Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure.

Authors: 
Journal:  Arch Intern Med       Date:  1984-05

3.  Trends in hypertension control in the United States.

Authors:  C Lenfant; E J Roccella
Journal:  Chest       Date:  1984-09       Impact factor: 9.410

4.  Sounding board. Risks of correcting the risks of coronary disease and stroke with drugs.

Authors:  M F Oliver
Journal:  N Engl J Med       Date:  1982-02-04       Impact factor: 91.245

5.  Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.

Authors:  M H Frick; O Elo; K Haapa; O P Heinonen; P Heinsalmi; P Helo; J K Huttunen; P Kaitaniemi; P Koskinen; V Manninen
Journal:  N Engl J Med       Date:  1987-11-12       Impact factor: 91.245

6.  Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin.

Authors:  P L Canner; K G Berge; N K Wenger; J Stamler; L Friedman; R J Prineas; W Friedewald
Journal:  J Am Coll Cardiol       Date:  1986-12       Impact factor: 24.094

7.  Health policy for treating hyperlipidemia: analogy with hypertension and prospects for the next decade.

Authors:  S B Hulley; M J Martin
Journal:  Am J Cardiol       Date:  1986-06-27       Impact factor: 2.778

8.  Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel.

Authors: 
Journal:  Arch Intern Med       Date:  1988-01

Review 9.  Risk factor modification after myocardial infarction.

Authors:  D Siegel; D Grady; W S Browner; S B Hulley
Journal:  Ann Intern Med       Date:  1988-08-01       Impact factor: 25.391

  9 in total
  3 in total

1.  Effects of atorvastatin 10 mg/d on insulin resistance: A 12-week, open-label study in hyperlipidemic patients.

Authors:  Filiz Ozerkan; Oner Ozdogan; Mehdi Zoghi; Sanem Nalbantgil; Oğuz Yavuzgil; M Remzi Önder
Journal:  Curr Ther Res Clin Exp       Date:  2006-01

2.  Low-Grade Inflammation, Oxidative Stress and Risk of Invasive Post-Menopausal Breast Cancer - A Nested Case-Control Study from the Malmö Diet and Cancer Cohort.

Authors:  Joana A Dias; Gunilla N Fredrikson; Ulrika Ericson; Bo Gullberg; Bo Hedblad; Gunnar Engström; Signe Borgquist; Jan Nilsson; Elisabet Wirfält
Journal:  PLoS One       Date:  2016-07-08       Impact factor: 3.240

Review 3.  There is urgent need to treat atherosclerotic cardiovascular disease risk earlier, more intensively, and with greater precision: A review of current practice and recommendations for improved effectiveness.

Authors:  Michael E Makover; Michael D Shapiro; Peter P Toth
Journal:  Am J Prev Cardiol       Date:  2022-08-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.